Verrica Pharmaceuticals (VRCA) to Release Quarterly Earnings on Monday

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 13th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Verrica Pharmaceuticals had a negative net margin of 1,307.47% and a negative return on equity of 119.46%. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.10 million. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Price Performance

Shares of VRCA traded up $0.23 during mid-day trading on Thursday, hitting $7.84. 106,916 shares of the company traded hands, compared to its average volume of 166,209. Verrica Pharmaceuticals has a one year low of $2.86 and a one year high of $7.95. The company has a current ratio of 4.55, a quick ratio of 4.49 and a debt-to-equity ratio of 2.22. The business has a 50-day moving average of $6.13 and a 200 day moving average of $5.36. The stock has a market capitalization of $332.57 million, a price-to-earnings ratio of -5.42 and a beta of 1.82.

Analysts Set New Price Targets

VRCA has been the topic of several research analyst reports. HC Wainwright increased their price target on shares of Verrica Pharmaceuticals from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Friday, March 1st. Needham & Company LLC restated a "buy" rating and issued a $8.00 price objective on shares of Verrica Pharmaceuticals in a report on Wednesday, April 10th.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.